Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) just unveiled an announcement.
Shanghai Bio-heart Biological Technology Co., Ltd. announced a delay in the dispatch of a circular related to a major transaction involving the disposal of equity interest in a subsidiary and proposed amendments to its Articles of Association. The circular, which contains critical financial information and agreements, will now be sent out by January 27, 2025, instead of the initially planned date. Additionally, the company has scheduled an Extraordinary General Meeting for February 13, 2025, and will close the register of members of H shares from February 4 to February 13 to determine shareholder entitlements for voting.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-heart Biological Technology Co., Ltd. is a joint stock company based in the People’s Republic of China. It operates within the biotechnology industry, focusing on the development of biological technology solutions.
YTD Price Performance: -5.49%
Average Trading Volume: 27,796
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$648.8M
For a thorough assessment of 2185 stock, go to TipRanks’ Stock Analysis page.
